Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow.

Trial Profile

Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2013

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms MRD-1
  • Sponsors Novartis
  • Most Recent Events

    • 29 Dec 2009 Trial acronym MRD-1 identified as reported by ClinicalTrials.gov.
    • 29 Dec 2009 Actual patient number (96) added as reported by ClinicalTrials.gov.
    • 29 Dec 2009 Planned end date (Nov 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top